Verve Therapeutics, Inc. - VERV STOCK NEWS

Verve Therapeutics has announced a leadership update with Troy Lister, Ph.D., being promoted to Chief Scientific Officer (CSO), effective June 21, 2024. Lister has been with Verve for two years, bringing over 15 years of experience, including roles at Spero Therapeutics, Novartis, and AstraZeneca.

Andrew Bellinger, M.D., Ph.D., the outgoing CSO who has served since 2019, will continue in an advisory capacity. Bellinger significantly contributed to Verve's pipeline development and preclinical and clinical programs.

CEO Sekar Kathiresan, M.D., praised both Lister and Bellinger for their contributions and leadership in advancing Verve's mission to develop gene-editing medicines for cardiovascular disease.

Verve Therapeutics, a clinical-stage biotechnology company specializing in gene editing for cardiovascular disease, announced its participation in two upcoming investor conferences. Management will engage in fireside chats at the Jefferies Global Healthcare Conference on June 6, 2024, at 1 p.m. ET in New York, NY, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 8 a.m. ET in Miami Beach, FL. Live webcasts of these events will be available on the company's website and will remain accessible for 30 days post-event.

Verve Therapeutics reported pipeline updates and financial results for the first quarter of 2024. The company dosed the first patient in the Heart-2 Phase 1b clinical trial of VERVE-102, with plans to initiate the VERVE-201 clinical trial in the second half of the year. Verve also received a milestone payment from Eli Lilly for a gene editing program targeting Lp(a). The company's cash position is strong, with $606.4 million in cash and marketable securities, providing runway into late 2026.

Verve Therapeutics announced the dosing of the first patient in the Heart-2 Phase 1b clinical trial evaluating VERVE-102, an investigational in vivo base editing medicine designed to reduce blood low-density lipoprotein cholesterol. The trial is enrolling patients with heterozygous familial hypercholesterolemia or premature coronary artery disease. VERVE-102 aims to permanently inactivate the PCSK9 gene in the liver, providing sustained reductions in LDL-C levels after a single treatment.

Verve Therapeutics granted equity awards to ten new employees under the company's 2024 Inducement Stock Incentive Plan. The employees received stock options and restricted stock units, totaling 64,200 shares and 56,100 RSUs. The options have an exercise price of $6.01 per share and will vest over four years, while the RSUs will vest annually over four years.

Verve Therapeutics announces updates from the Heart-1 Phase 1b clinical trial of VERVE-101, demonstrating significant LDL-C reduction of up to 73% at 0.45 mg/kg dose. However, enrollment in the trial is paused due to observed laboratory abnormalities in the sixth participant. Verve is prioritizing the development of VERVE-102, with clearance for the Heart-2 clinical trial expected in 2Q 2024.

Verve Therapeutics granted equity awards to six new employees under the 2024 Inducement Stock Incentive Plan. The awards include stock options for 91,200 shares and 45,800 restricted stock units, with an exercise price of $13.28 per share. The options have a 10-year term and will vest over four years, while the RSUs will vest annually over four years.

Verve Therapeutics grants equity awards to new employees under the 2024 Inducement Stock Incentive Plan, with 16,300 RSUs vested over four years.

Verve Therapeutics reports pipeline updates and financial results for Q4 2023, with $624 million in cash, proof-of-concept data for VERVE-101, and upcoming clinical trials for PCSK9 and ANGPTL3 in 2024.